Correlation between the single nucleotide polymorphism of PLA2G7 gene and the activity and concentration of Lp-PLA2

doi:10.3969/j.issn.1673-8640.2026.06.005

Abstract

Abstract:

Objective To investigate the relationship between PLA2G7 gene single nucleotide polymorphisms（SNP）and the activity and concentration of lipoprotein-associated phospholipase A2 （Lp-PLA2）. Methods A total of 100 patients with coronary artery disease （CAD） diagnosed by coronary angiography at Zhongshan Hospital of Fudan University from January 2024 to December 2024 and 100 healthy subjects （healthy control group） were enrolled. The serum total cholesterol （TC），triglyceride （TG），high-density lipoprotein cholesterol （HDL-C），low-density lipoprotein cholesterol （LDL-C） and Lp-PLA2 activity and concentration were determined，as well as the SNP of PLA2G7 gene at rs1805017，rs1805018，rs76863441 and rs1051931 loci. Spearman correlation analysis was used to evaluate the correlation between different SNP sites of PLA2G7 gene. Multiple linear models were used to analyze the influencing factors of Lp-PLA2 activity and concentration. Results There was statistical significance in serum TC，TG，LDL-C，HDL-C levels and Lp-PLA2 activity between CAD group and healthy control group （P<0.05），while there was no statistical significance in Lp-PLA2 concentration between the 2 groups （P>0.05）. The genotype distribution of PLA2G7 gene at rs1051931 locus had statistical significance between CAD group and healthy control group （P=0.036）. The genotypes at other loci showed no statistical significance between the 2 groups （P>0.05）. Among all the subjects，the PLA2G7 gene I198T locus mutation was positively correlated with V279F locus mutation （r=0.706，P<0.001），and V379A locus mutation was positively correlated with R92H and I198T locus mutations（r values were 0.256 and 0.140，P<0.05）. In CAD group and healthy control group，the carriers of V279F and I198T locus mutation （including heterozygous and homozygous mutations） had lower Lp-PLA2 activity and concentration than wild-type （P<0.05）. After adjusting for age，gender and blood lipid indicators，V279F and I198T were locus independent influencing factors for the decrease in Lp-PLA2 concentration （P<0.05），and V279F mutation was an independent influencing factor for the decrease in Lp-PLA2 activity （P<0.001）. Conclusions The SNP of PLA2G7 gene at rs1805018 and rs76863441 loci are related to Lp-PLA2 activity and concentration，and they are independent influencing factors for the decrease in Lp-PLA2 level.

Key words: Lipoprotein-associated phospholipase A2, Gene, Single nucleotide polymorphism, Concentration, Activity, Coronary artery disease

CLC Number:

R446.7

SHAO Wenqi, ZHOU Yan, XIONG Ying, ZHU Jing, GUO Jiajie, PAN Baishen, WANG Beili, GUO Wei. Correlation between the single nucleotide polymorphism of PLA2G7 gene and the activity and concentration of Lp-PLA2[J]. Laboratory Medicine, 2026, 41(6): 547-553.

Figures/Tables 10

References 18

[1]	中国血脂管理指南修订联合专家委员会, 李建军, 赵水平, 等. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志, 2023, 51(3):221-255.
[2]	HUANG F, WANG K, SHEN J. Lipoprotein-associated phospholipase A2:the story continues[J]. Med Res Rev, 2020, 40(1):79-134. DOI URL
[3]	Lp-PLA(2) Studies Collaboration, THOMPSON A, GAO P, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease,stroke,and mortality:collaborative analysis of 32 prospective studies[J]. Lancet, 2010, 375(9725):1536-1544. DOI URL
[4]	POLFUS L M, GIBBS R A, BOERWINKLE E. Coronary heart disease and genetic variants with low phospholipase A2 activity[J]. N Engl J Med, 2015, 372(3):295-296. DOI URL
[5]	MILLWOOD I Y, BENNETT D A, WALTERS R G, et al. Lipoprotein-associated phospholipase a2 loss-of-function variant and risk of vascular diseases in 90 000 Chinese adults[J]. J Am Coll Cardiol, 2016, 67(2):230-231.
[6]	LUQMAN H, MOHAMMED N, KRISHNA MOHAN I, et al. Unveiling the synergy of serum lipoprotein-associated phospholipase A2 and PLA2G 7 gene polymorphism (rs1805017) as key determinants of coronary artery disease risk and severity:implications for early intervention[J]. Cureus, 2024, 16(11):e74045.
[7]	MA S, DING L, CAI M, et al. Association Lp-PLA2 gene polymorphisms with coronary heart disease[J]. Dis Markers, 2022, 2022:9775699.
[8]	QIN L, MA Q, ZHANG C, et al. Genetic polymorphism of lipoprotein-associated phospholipase A2 influences susceptibility to gestational diabetes mellitus in Chinese population[J]. Diabetes Metab Syndr Obes, 2023, 16:3285-3294. DOI URL
[9]	CURY R C, ABBARA S, ACHENBACH S, et al. CAD-RADS™:coronary artery disease-reporting and data system:an expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT),the American College of Radiology (ACR) and the North American Society for Cardiovascular Imaging (NASCI). Endorsed by the American College of Cardiology[J]. J Am Coll Radiol, 2016, 13(12 Pt A):1458-1466.e9. DOI URL
[10]	WANG Y, SHI Y, WU Z, et al. The association of PLA2G7 gene polymorphisms with serum Lp-PLA2 activity and lipid profile in Han Chinese patients with coronary heart disease[J]. Pharmgenomics Pers Med, 2024, 17:563-572.
[11]	STAFFORINI D M, SATOH K, ATKINSON D L, et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase[J]. J Clin Invest, 1996, 97(12):2784-2791. DOI PMID
[12]	SUTTON B S, CROSSLIN D R, SHAH S H, et al. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets[J]. Hum Mol Genet, 2008, 17(9):1318-1328. DOI PMID
[13]	SONG K, NELSON M R, APONTE J, et al. Sequencing of Lp-PLA2-encoding PLA2G7 gene in 2000 Europeans reveals several rare loss-of-function mutations[J]. Pharmacogenomics J, 2012, 12(5):425-431. DOI
[14]	XU M, YULONG L, QI S, et al. Comparison of Lp-PLA2 activity,Lp-PLA2 mass and Lp-PLA2 mRNA in acute coronary syndrome patients[J]. J Integr Cardiol Open Access, 2021, 4 (3):3-7.
[15]	TSELEPIS A D. Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role[J]. J Biomed Res, 2018, 31(1):13-22.
[16]	QUE X, HUNG M Y, YEANG C, et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice[J]. Nature, 2018, 558(7709):301-306. DOI
[17]	RIDKER P M, MACFADYEN J G, WOLFERT R L, et al. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy:an analysis from the JUPITER trial[J]. Clin Chem, 2012, 58(5):877-886. DOI URL
[18]	GREGSON J M, FREITAG D F, SURENDRAN P, et al. Genetic invalidation of Lp-PLA2 as a therapeutic target:Large-scale study of five functional Lp-PLA2-lowering alleles[J]. Eur J Prev Cardiol, 2017, 24(5):492-504. DOI URL

位点名称	引物（5'~3'）	探针（5'~3'）
rs1805017（R92H）	上游：CAAGAAATTTGCTAAGACCCCAAA 下游：AGGGCACCTTCTTGCGTTT	ATAATGATCACCTTGACACCC-FAM
rs1805018（I198T）	上游：GCAATGTACCTGCTCATTTCGT 下游：AAACATGGGTCAGATGAGGAAGG	CTGCAGAAACAGGGGACA-FAM
rs76863441（V279F）	上游：ACCTGAATCTCTGATCTTCA 下游：ATCATGCTTTTTCAAATAGGACTCT	TGGAGTGAATAACCGTTGCTCCA-FAM
rs1051931（V379A）	上游：AGACAGCTTTGTCCTGAGATTCAT 下游：TAGGGGTTCAGTCCACCAGA	AAATGCAGCTATTGATCTTAGCAAC-FAM

位点名称	引物（5'~3'）	探针（5'~3'）
rs1805017（R92H）	上游：CAAGAAATTTGCTAAGACCCCAAA 下游：AGGGCACCTTCTTGCGTTT	ATAATGATCACCTTGACACCC-FAM
rs1805018（I198T）	上游：GCAATGTACCTGCTCATTTCGT 下游：AAACATGGGTCAGATGAGGAAGG	CTGCAGAAACAGGGGACA-FAM
rs76863441（V279F）	上游：ACCTGAATCTCTGATCTTCA 下游：ATCATGCTTTTTCAAATAGGACTCT	TGGAGTGAATAACCGTTGCTCCA-FAM
rs1051931（V379A）	上游：AGACAGCTTTGTCCTGAGATTCAT 下游：TAGGGGTTCAGTCCACCAGA	AAATGCAGCTATTGATCTTAGCAAC-FAM

组别	例数	TC/（mmol·L^-1）	TG/（mmol·L^-1）	LDL-C/（mmol·L^-1）	HDL-C/（mmol·L^-1）	Lp-PLA2活性/（U·L^-1）	Lp-PLA2质量/（μg·L^-1）
正常对照组	100	4.66（4.21~4.99）	1.13（0.91~1.41）	2.70（2.33~3.18）	1.28（1.12~1.61）	413.00（337.53~479.20）	104.90（74.48~126.00）
CAD组	100	3.59（3.09~4.41）	1.63（1.11~2.38）	1.69（1.26~2.27）	1.03（0.92~1.16）	371.30（286.18~490.10）	97.70（74.20~126.80）
U值		2 200.50	2 932.00	1 837.00	2 169.00	4 162.50	4 829.50
P值		<0.001	<0.001	<0.001	<0.001	0.041	0.667

组别	例数	TC/（mmol·L^-1）	TG/（mmol·L^-1）	LDL-C/（mmol·L^-1）	HDL-C/（mmol·L^-1）	Lp-PLA2活性/（U·L^-1）	Lp-PLA2质量/（μg·L^-1）
正常对照组	100	4.66（4.21~4.99）	1.13（0.91~1.41）	2.70（2.33~3.18）	1.28（1.12~1.61）	413.00（337.53~479.20）	104.90（74.48~126.00）
CAD组	100	3.59（3.09~4.41）	1.63（1.11~2.38）	1.69（1.26~2.27）	1.03（0.92~1.16）	371.30（286.18~490.10）	97.70（74.20~126.80）
U值		2 200.50	2 932.00	1 837.00	2 169.00	4 162.50	4 829.50
P值		<0.001	<0.001	<0.001	<0.001	0.041	0.667

组别	例数	CC/ [例（%）]	CT/ [例（%）]	TT/ [例（%）]
正常对照组	100	64（64）	32（32）	4（4）
CAD组	100	59（59）	35（35）	6（6）
χ²值		0.738
P值		0.691